Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis

Marcelo T. Bozza(Boston Children's Hospital), Abhay R. Satoskar(Boston Children's Hospital), Guosheng Lin(Boston Children's Hospital), Bao Lu(Boston Children's Hospital), Alison A. Humbles(Boston Children's Hospital), Craig Gérard(Boston Children's Hospital), John R. David(Boston Children's Hospital)
The Journal of Experimental Medicine
January 18, 1999
Cited by 551Open Access
Full Text

Abstract

To study the biologic role of migration inhibitory factor (MIF), a pleiotropic cytokine, we generated a mouse strain lacking MIF by gene targeting in embryonic stem cells. Analysis of the role of MIF during sepsis showed that MIF-/- mice were resistant to the lethal effects of high dose bacterial lipopolysaccharide (LPS), or Staphylococcus aureus enterotoxin B (SEB) with D-galactosamine and had lower plasma levels of tumor necrosis factor alpha (TNF-alpha) than did wild-type mice, but normal levels of interleukin (IL)-6 and IL-10. When stimulated with LPS and interferon gamma, macrophages from MIF-/- mice showed diminished production of TNF-alpha, normal IL-6 and IL-12, and increased production of nitric oxide. MIF-/- animals cleared gram-negative bacteria Pseudomonas aeruginosa instilled into the trachea better than did wild-type mice and had diminished neutrophil accumulation in their bronchoalveolar fluid compared to the wild-type mice. Thioglycollate elicited peritoneal exudates in uninfected MIF-/- mice, but showed normal neutrophil accumulation. Finally, the findings of enhanced resistance to P. aeruginosa and resistance to endotoxin-induced lethal shock suggest that the counteraction or neutralization of MIF may serve as an adjunct therapy in sepsis.


Related Papers

No related papers found

Powered by citation graph analysis